The Pentagon just unveiled a new platform it calls Pathfinder.
No, it’s not a new robotic weapons system… or a new high-tech tank… or even an innovative mapping system.
Instead, this is a program that addresses the Pentagon as a huge bureaucracy, instead of as a fighting force.
Pathfinder is a new program to migrate tons of data, some of it quite sensitive, to the cloud. And the U.S. Department of Defense is contracting with cloud leader Amazon Web Services in a deal that could eventually be worth billions to make it happen.
As you might imagine in this era of cyberattacks, not everyone in Washington is on board with the massive data migration.
They worry that the Pentagon is exposing itself to hackers who may come from China, North Korea, or Russia. After all, black-hat teams tied to those three nations attempt to penetrate our military networks on an almost hourly basis.
Here’s the thing. There’s a relatively new approach out there that offers far more security, not to mention a permanent record of every single transaction involving a military budget totaling more than $750 billion.
It’s a system I call the Milblock.
In a moment, I’ll explain just what I’m talking about.
And then I’ll show you how investing in this field could land you a 10-bagger…
Medical marijuana is one of the biggest healthcare stories out there right now.
We know that cannabis is a godsend for cancer patients, who use it to control their nausea and increase their appetite following chemotherapy.
Researchers are proving every day that cannabis-based drugs are effective against extreme pain, epilepsy, multiple sclerosis, and other ailments.
Plus, because of marijuana’s effectiveness in the fight against pain, everyone from doctors to law enforcement leaders are looking to use weed to help end the ongoing – and devastating – opioid crisis.
All that means medical marijuana is also one of the best investment opportunities out there.
That’s why I’ve recommended GW Pharmaceuticals PLC (Nasdaq ADR: GWPH) to you again and again.
But when it comes to medical marijuana, there’s a big problem.
Marijuana is probably the least studied cash crop in the world.
Researchers working to discover and refine the medicinal properties of cannabis have been greatly hampered by the Drug Enforcement Agency’s (DEA) classification of the plant as a Schedule 1 drug. That means the federal government deems marijuana as having no accepted medical use, like meth or heroin.
That stance has cut down on the sort of well-funded research that’s needed to usher in the next round of cannabis-based wonder drugs.
But that doesn’t mean no research is happening. After all, GW Pharma and other biotech firms have produced a first round of weed-based drugs.
In fact, there’s a small but growing cottage industry of tiny startups focused on the genetic testing of cannabis to help those biotechs
Some marijuana analytics startups, like Steep Hill, are developing their own gene-sequencing systems – and that’s something very exciting I plan to tell you more about soon.
But most, including Medicinal Genomics, are using state-of-the-art gene-sequencing equipment from the company I want to tell you about today.
This dynamic industry leader is a pioneer in the genetic testing equipment field. And now it’s equipment is crucial for medical marijuana pioneers.
If you got in when I first recommended this stock just a few months ago, you’ve already made nearly 19%.
But thanks to the medical marijuana sector’s interest and several more catalysts I’ll tell you about below, it’s got a lot further to run.
Take a look…